Previous Article | Next Article 
J Virol. 1984 April; 50(1): 50-55
Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.
J C Lin,
M C Smith and
J S Pagano
ABSTRACT
The effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), a new antiviral drug, and acyclovir (ACV) [9-(2-hydroxyethoxymethyl)guanine] on the replication of Epstein-Barr virus (EBV) were compared. Both drugs inhibited EBV DNA replication in P3HR-1 cells and superinfected Raji cells, but neither inhibited replication of the plasmid form of the EBV genome in latently infected Raji cells. However, DHPG had a more prolonged inhibitory effect than ACV. Although the effect of the drugs is prompt, the kinetics of inhibition of EBV replication indicated that a drug exposure of 14 days was needed to reduce the EBV genome copy number to the residual plasmid level (30 copies per cell). The inhibitory effect of ACV was readily reversed within 11 days after removal of the drug, in contrast to the more prolonged effect exerted by DHPG, which persisted for more than 21 days. The 50% inhibitory doses for cell growth of ACV and DHPG were estimated to be 250 and 200 microM, respectively. The viral 50% and 90% effective doses of inhibition were, respectively, 0.3 and 9 microM for ACV and 0.05 and 3 microM for DHPG. The therapeutic indices (50% inhibitory dose/50% effective dose) for ACV and DHPG were 833 and 4,000, respectively. Synthesis of EBV-associated polypeptides was also affected. In superinfected Raji cells, ACV (100 microM) and DHPG (30 microM) inhibited synthesis of polypeptides with molecular weights of 145,000 and 140,000; in addition, synthesis of polypeptides with molecular weights of 110,000 and 85,000 was markedly reduced by DHPG but not by ACV. However, after drug removal, the inhibitory effect of ACV on polypeptide synthesis was abolished in contrast to the more persistent effect of DHPG.
J Virol. 1984 April; 50(1): 50-55
This article has been cited by other articles:
-
Perrine, S. P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S. J., Di Nicola, M., Gianni, A. M., Klein, C., Horwitz, S., Faller, D. V.
(2007). A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood
109: 2571-2578
[Abstract]
[Full Text]
-
Ressing, M. E., Keating, S. E., van Leeuwen, D., Koppers-Lalic, D., Pappworth, I. Y., Wiertz, E. J. H. J., Rowe, M.
(2005). Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection. J. Immunol.
174: 6829-6838
[Abstract]
[Full Text]
-
Feng, W.-h., Hong, G., Delecluse, H.-J., Kenney, S. C.
(2004). Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas. J. Virol.
78: 1893-1902
[Abstract]
[Full Text]
-
Andreone, P., Gramenzi, A., Lorenzini, S., Biselli, M., Cursaro, C., Pileri, S., Bernardi, M.
(2003). Posttransplantation Lymphoproliferative Disorders. Arch Intern Med
163: 1997-2004
[Abstract]
[Full Text]
-
Keating, S., Prince, S., Jones, M., Rowe, M.
(2002). The Lytic Cycle of Epstein-Barr Virus Is Associated with Decreased Expression of Cell Surface Major Histocompatibility Complex Class I and Class II Molecules. J. Virol.
76: 8179-8188
[Abstract]
[Full Text]
-
Feng, W.-h., Israel, B., Raab-Traub, N., Busson, P., Kenney, S. C.
(2002). Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors. Cancer Res.
62: 1920-1926
[Abstract]
[Full Text]
-
Tierney, R. J., Kirby, H. E., Nagra, J. K., Desmond, J., Bell, A. I., Rickinson, A. B.
(2000). Methylation of Transcription Factor Binding Sites in the Epstein-Barr Virus Latent Cycle Promoter Wp Coincides with Promoter Down-Regulation during Virus-Induced B-Cell Transformation. J. Virol.
74: 10468-10479
[Abstract]
[Full Text]
-
Westphal, E. M., Blackstock, W., Feng, W., Israel, B., Kenney, S. C.
(2000). Activation of Lytic Epstein-Barr Virus (EBV) Infection by Radiation and Sodium Butyrate in Vitro and in Vivo: A Potential Method for Treating EBV-positive Malignancies. Cancer Res.
60: 5781-5788
[Abstract]
[Full Text]
-
Zacny, V. L., Gershburg, E., Davis, M. G., Biron, K. K., Pagano, J. S.
(1999). Inhibition of Epstein-Barr Virus Replication by a Benzimidazole L-Riboside: Novel Antiviral Mechanism of 5,6-Dichloro-2-(Isopropylamino)-1-beta -L-Ribofuranosyl-1H-Benzimidazole. J. Virol.
73: 7271-7277
[Abstract]
[Full Text]
-
Westphal, E.-M., Mauser, A., Swenson, J., Davis, M. G., Talarico, C. L., Kenney, S. C.
(1999). Induction of Lytic Epstein-Barr Virus (EBV) Infection in EBV-associated Malignancies Using Adenovirus Vectors in Vitro and in Vivo. Cancer Res.
59: 1485-1491
[Abstract]
[Full Text]
-
Neyts, J., De Clercq, E.
(1998). In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents. Antimicrob. Agents Chemother.
42: 170-172
[Abstract]
[Full Text]
-
Crumpacker, C. S.
(1996). Ganciclovir. NEJM
335: 721-729
[Full Text]
Copyright © 1984 by the American Society for Microbiology. All rights reserved.